February 02, 2021
Investors in biopharmaceutical company NewLink Genetics Corp. told a Manhattan federal judge that they'd reached a $13.5 million deal to settle their proposed securities class action accusing the company and its co-founders of misrepresenting details of a pancreatic cancer drug trial.
August 01, 2018
Biopharmaceutical company NewLink Genetics Corp. urged a New York federal court Tuesday to dismiss for a second time a proposed investor class action alleging executives' misrepresentations about a pancreatic cancer treatment artificially inflated stock prices, saying the court already determined the statements were "non-actionable opinions."